Sensoril (Ashwagandha)
Natreon, root + leaf extract
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Dietary ingredient (not FDA-evaluated for efficacy)
Reference only. Not medical advice.
What can go wrong
More sedating than KSM-66 (the root+leaf, higher-withanolide profile). Testosterone-specific evidence is limited; most data are stress/cognition endpoints.
This is something to take to a clinician. The Atlas can tell you what is known about sensoril (ashwagandha) in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Sensoril is a branded ashwagandha extract from Natreon, made from both root and leaf and standardized to a higher withanolide content (~10%+). It is dosed lower than KSM-66 (often ~125-250 mg) and is generally positioned for stress/sleep, with a more sedating profile, rather than as a primary testosterone product. Its testosterone evidence is thinner than KSM-66's.
The higher-withanolide, more sedating ashwagandha extract.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
What people get wrong
Often saidSensoril and KSM-66 are interchangeable
ActuallyThey are different extracts (root+leaf vs root-only; different withanolide content and dose), studied for somewhat different endpoints. They are not equivalent for testosterone claims.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Supplier
- Natreon
- Source
- Root + leaf, ~10%+ withanolides
- Typical dose
- 125-250 mg
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Sensoril (Ashwagandha). A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.